Literature DB >> 7810820

Seroepidemiologic screening of Echinococcus multilocularis infection in a European area endemic for alveolar echinococcosis.

S Bresson-Hadni1, J J Laplante, D Lenys, P Rohmer, B Gottstein, P Jacquier, P Mercet, J P Meyer, J P Miguet, D A Vuitton.   

Abstract

In a serologic survey for Echinococcus multilocularis infection, we screened sera from 7,884 subjects from the Doubs Departement in France, an area endemic for alveolar echinococcosis (AE) of the liver. An enzyme-linked immunosorbent assay (ELISA) with a highly species-specific antigen (Em2) and an E. multilocularis crude antigen (Emc) was used for screening. An evaluation of the cost/benefit relationship of this screening, followed by therapeutic management of patients, was made and compared with the actual cost of the follow-up and treatment of the disease in symptomatic cases in this endemic area. Antibody reactions to Em2 and/or Emc made possible the detection of eight asymptomatic clinical cases (seroprevalence averaging 1/1,000), with typical lesions of active AE revealed by abdominal ultrasonography and computed tomography. All were seropositive using the Emc ELISA but two were seronegative using the Em2 ELISA. In five additional seropositive cases, the radiologic investigations revealed small calcified lesions similar to the lesions of abortive AE previously found in Alaska. The cost of this serologic screening program per screened subject and per diagnosed case averaged 50.00 French Francs (FF) (U.S. $8.60) and 60,000.00 FF (U.S. $10,909.00), respectively. The cost of diagnosis, follow-up and treatment of the patients was 5,086.00 FF (U.S. $929.00) per patient per month in the case of diseases diagnosed by the screening program and 7,086.00 FF (U.S. $1,288.00) per patient per month for patients with symptomatic AE. This survey indicates a high prevalence of AE in the target area; it confirms the long latency period of the larval growth in human AE and shows that abortive AE is present in Europe. The use of both the Emc and Em2 ELISAs seems to be better than using the Em2 ELISA alone. The cost of the hospitalization and treatment of the eight screened patients would appear to be relatively high. Even though two of them were asymptomatic, they had very severe forms of the disease. In fact, the total cost was much lower than the actual cost of the disease when diagnosed from clinical symptoms.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7810820     DOI: 10.4269/ajtmh.1994.51.837

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  21 in total

Review 1.  Cavitary pulmonary disease.

Authors:  L Beth Gadkowski; Jason E Stout
Journal:  Clin Microbiol Rev       Date:  2008-04       Impact factor: 26.132

2.  Evaluation of the diagnostic value of the immunoblotting and ELISA tests using recombinant Em18 antigen in human alveolar echinococcosis from Xingjiang China.

Authors:  Xiao-Juan Bi; Yin-Mei Shao; Liang Li; Yan Wang; Chuan-Shan Zhang; Guo-Dong Lü; Tuerganaili Aji; Jun Li; Wen-Bao Zhang; Hao Wen; Ren-Yong Lin
Journal:  Exp Ther Med       Date:  2018-08-01       Impact factor: 2.447

3.  Echinococcus multilocularis metacestodes modulate cellular cytokine and chemokine release by peripheral blood mononuclear cells in alveolar echinococcosis patients.

Authors:  M P Hübner; B J Manfras; M C Margos; D Eiffler; W H Hoffmann; H Schulz-Key; P Kern; P T Soboslay
Journal:  Clin Exp Immunol       Date:  2006-08       Impact factor: 4.330

4.  Distinctive cytokine, chemokine, and antibody responses in Echinococcus multilocularis-infected patients with cured, stable, or progressive disease.

Authors:  Xiangsheng Huang; Beate Grüner; Christian J Lechner; Peter Kern; Peter T Soboslay
Journal:  Med Microbiol Immunol       Date:  2014-02-09       Impact factor: 3.402

5.  Resistance/susceptibility to Echinococcus multilocularis infection and cytokine profile in humans. I. Comparison of patients with progressive and abortive lesions.

Authors:  V Godot; S Harraga; I Beurton; M Deschaseaux; E Sarciron; B Gottstein; D A Vuitton
Journal:  Clin Exp Immunol       Date:  2000-09       Impact factor: 4.330

Review 6.  Echinococcus multilocularis and its intermediate host: a model of parasite-host interplay.

Authors:  Dominique Angèle Vuitton; Bruno Gottstein
Journal:  J Biomed Biotechnol       Date:  2010-03-21

Review 7.  Echinococcosis and allergy.

Authors:  Dominique A Vuitton
Journal:  Clin Rev Allergy Immunol       Date:  2004-04       Impact factor: 8.667

Review 8.  Biological, epidemiological, and clinical aspects of echinococcosis, a zoonosis of increasing concern.

Authors:  Johannes Eckert; Peter Deplazes
Journal:  Clin Microbiol Rev       Date:  2004-01       Impact factor: 26.132

Review 9.  Epidemiology of echinococcosis.

Authors:  Thomas Romig
Journal:  Langenbecks Arch Surg       Date:  2003-08-22       Impact factor: 3.445

10.  European echinococcosis registry: human alveolar echinococcosis, Europe, 1982-2000.

Authors:  Petra Kern; Karine Bardonnet; Elisabeth Renner; Herbert Auer; Zbigniew Pawlowski; Rudolf W Ammann; Dominique A Vuitton; Peter Kern
Journal:  Emerg Infect Dis       Date:  2003-03       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.